Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden

• Published in: Journal of rheumatology Vol. 29; no. 4; p. 737
• Main Authors: Uddhammar, Agneta, Eriksson, Anna-Lena, Nyström, Lennarth, Stenling, Roger, Rantapää-Dahlqvist, Solbritt
• Format: Journal Article
• Language: English
• Published: Canada 01.04.2002
• Subjects: Aged; Aged, 80 and over; Cardiovascular Diseases - complications; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - mortality; Cause of Death; Comorbidity; Dose-Response Relationship, Drug; Female; Giant Cell Arteritis - complications; Giant Cell Arteritis - drug therapy; Giant Cell Arteritis - mortality; Glucocorticoids - administration & dosage; Glucocorticoids - therapeutic use; Humans; Hypertension; Male; Middle Aged; Polymyalgia Rheumatica - complications; Polymyalgia Rheumatica - drug therapy; Polymyalgia Rheumatica - mortality; Prednisolone - administration & dosage; Prednisolone - therapeutic use; Risk Factors; Sex Factors; Survival Analysis; Survival Rate; Sweden - epidemiology; Sweden
• ISSN: 0315-162X

To study the cause of death pattern in patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR), and to analyze the effect of the disease, or its therapy, on the risk of a cardiovascular event (CVE). Patients with biopsy proven GCA or with PMR, whose condition was diagnosed between 1973 and 1979, were followed until December 31, 1995. The standardized mortality ratio (SMR) was estimated using data for the population of Västerbotten, Northern Sweden, as reference value. Information for sex, age at diagnosis, erythrocyte sedimentation rate (ESR) at diagnosis, corticosteroid therapy, comorbidity from diagnosis, and date and cause of death was collected. A total of 136 patients with GCA and 35 with PMR were identified. At the time of followup 114 patients with GCA and 25 with PMR were deceased. The overall mortality was significantly increased in the female patients, SMR = 133 (95% CI 110-162). Death due to cardiovascular disease (CVD) was significantly increased in both women and men, SMR = 149 (95% CI 118-189) and 158 (95% CI 112-224), respectively, and mainly due to ischemic heart disease. An excess mortality was found in women with the highest ESR, the highest prescribed dose of prednisolone at diagnosis, or a daily prednisolone dose of 10 mg or more one year after diagnosis. In multiple Cox regression analysis, male sex and hypertension significantly increased the risk of a CVE. Death due to CVD was increased in patients with GCA. Increased mortality was related to either the corticosteroid therapy itself or insufficient control of inflammation.